Modality
Gene Therapy
MOA
IL-17i
Target
AuroraA
Pathway
Cell Cycle
NASHCSU
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
~Oct 2022
→ ~Jan 2024
Phase 2
~Apr 2024
→ ~Jul 2025
Phase 3
Oct 2025
→ Nov 2027
Phase 3Current
NCT03330236
318 pts·NASH
2025-10→2027-11·Completed
318 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-241w agoFast Track· NASH
2027-11-171.6y awayPh3 Readout· NASH
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q4
P3
Complet…
Catalysts
Fast Track
2026-03-24 · 1w ago
NASH
Ph3 Readout
2027-11-17 · 1.6y away
NASH
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03330236 | Phase 3 | NASH | Completed | 318 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |